BRCA2 and neoplasm: In a patient-derived xenograft humanized germline BRCA2-deficent model with an acquired secondary resistance mutation and a TMB of 12.2 mut/Mb, an anti-PD1 monoclonal antibody significantly slowed tumor growth and promoted tumor T-cell infiltration [64].